Clinical Pharmacokinetics and Pharmacodynamics of Direct Oral Anticoagulants in Patients with Renal Failure

European Journal of Drug Metabolism and Pharmacokinetics
Roberto Padrini

Abstract

A recent survey on the use of direct oral anticoagulants (DOACs) revealed that 43% of patients with atrial fibrillation and renal impairment were potentially overdosed and had a hazard ratio for major bleeding of 2.19. In this review, we analyse and discuss the effect of renal failure on the pharmacokinetics and pharmacodynamics of DOACs and of strategies proposed to adjust doses according to the level of renal dysfunction. The pharmacokinetic characteristics of available DOACs (dabigatran, rivaroxaban, apixaban, edoxaban, betrixaban) differ substantially as regards oral bioavailability, plasma protein binding and the relative involvement of renal and non-renal elimination. In this respect, 80% of dabigatran is excreted as an unchanged drug in urine, whereas edoxaban, rivaroxaban, apixaban and betrixiban are excreted unchanged by, respectively, 50, 33, 27 and 11% of the dose. Therefore, drug exposure (the area under the concentration-time curve, AUC) is expected to increase to differing extents, depending on the residual renal function and the contribution of the kidneys to the excretion of each drug. Our analysis found that the increased AUC in patients with severe renal dysfunction was greater than expected in the case of dab...Continue Reading

References

Mar 1, 1986·Clinical Pharmacokinetics·T D Bjornsson
Dec 1, 1981·British Journal of Clinical Pharmacology·G T Tucker
Aug 1, 1993·Clinical Pharmacology and Therapeutics·R OsborneM Slevin
Jun 30, 2004·Scandinavian Journal of Gastroenterology·H StridE S Björnsson
Nov 17, 2007·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Stefan BlechWilly Roth
Apr 5, 2008·Clinical Pharmacology and Therapeutics·T D NolinV Pichette
Oct 4, 2008·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Nirmala RaghavanDonglu Zhang
Feb 7, 2009·Drug Metabolism and Disposition : the Biological Fate of Chemicals·C WeinzD Lang
Jun 23, 2009·European Journal of Clinical Pharmacology·Roger K Verbeeck, Flora T Musuamba
Sep 25, 2009·Clinical Pharmacology and Therapeutics·A W Dreisbach
Jun 17, 2010·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Thomas EbnerWolfgang Wienen
Nov 12, 2010·Seminars in Dialysis·Thomas D Nolin, Mark L Unruh
Aug 19, 2011·Fundamental & Clinical Pharmacology·Reinhold Kreutz
Oct 1, 2011·Journal of Clinical Pharmacology·Sudharshan Hariharan, Rajanikanth Madabushi
Jan 18, 2012·Journal of Clinical Pharmacology·Judith NaudVincent Pichette
Sep 1, 2012·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Mohinder S BathalaJeanne Mendell
Jan 12, 2013·British Journal of Clinical Pharmacology·Wolfgang MueckMichael Becka
Jun 21, 2013·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Jeanne MendellMinggao Shi
Nov 8, 2014·British Journal of Clinical Pharmacology·Charles E FrostFrank LaCreta
Nov 25, 2014·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Peter Brønnum NielsenTorben Bjerregaard Larsen
May 1, 2015·Circulation Journal : Official Journal of the Japanese Circulation Society·Yukihiro KoretsuneMasahiro Yasaka
Sep 12, 2015·Journal of Clinical Pharmacology·Ming ChangCharles E Frost
Dec 25, 2015·The American Journal of Cardiology·Freddy Del-Carpio MunozPeter A Noseworthy
Jan 23, 2016·Clinical Pharmacology and Therapeutics·Kenta YoshidaShiew-Mei Huang
Feb 11, 2016·Molecules : a Journal of Synthetic Chemistry and Natural Product Chemistry·Milan RemkoRia Broer
Apr 22, 2016·American Journal of Nephrology·Clapton DiasMatthew R Weir
Sep 10, 2016·The Canadian Journal of Cardiology·Laurent MacleUNKNOWN CCS Atrial Fibrillation Guidelines Committee
Mar 18, 2017·Journal of the American Society of Nephrology : JASN·Thomas A MavrakanasMark L Lipman
May 16, 2017·The American Journal of Medicine·John FanikosPaul P Dobesh
Jun 10, 2017·Journal of the American College of Cardiology·Xiaoxi YaoPeter A Noseworthy
Jan 19, 2018·Nature Reviews. Cardiology·Jerrold H LevyJeffrey I Weitz

❮ Previous
Next ❯

Citations

Jan 17, 2020·Clinical Pharmacology in Drug Development·Peter H Hinderling, Thomas Papoian
Oct 28, 2019·Biological Trace Element Research·Xueying ZengGang Liu
Dec 31, 2019·Journal of Diabetes Research·Dana PrídavkováMarián Mokáň
May 28, 2020·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Chia Siang KowSyed Shahzad Hasan
Sep 27, 2020·Journal of Thrombosis and Haemostasis : JTH·Myrthe M A TooropLuuk J J Scheres
Apr 26, 2020·BMJ Evidence-based Medicine·Sheweidin AzizGrahame Taylor
Mar 4, 2021·Current Cardiology Reports·Evan M White, James C Coons
Mar 19, 2021·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Job HarenbergSvetlana Hetjens
Jun 22, 2020·The American Journal of Emergency Medicine·Gianni TurcatoAntonio Bonora
Jun 19, 2021·Cardiovascular Drugs and Therapy·Robert BenamouzigLaurent Fauchier
Aug 31, 2021·The Annals of Pharmacotherapy·Jessica A StarrMary Katherine Stuart
Sep 1, 2021·Medizinische Klinik, Intensivmedizin und Notfallmedizin·Georg Braun
Oct 9, 2021·European Heart Journal·Thomas F LüscherStavros V Konstantinides

❮ Previous
Next ❯

Related Concepts

Related Feeds

Atrial Filbrillation

Atrial fibrillation refers to the abnormal heart rhythm characterized by rapid and irregular beating of the atria. Here is the latest research.

Atrial Fibrillation

Atrial fibrillation is a common arrhythmia that is associated with substantial morbidity and mortality, particularly due to stroke and thromboembolism. Here is the latest research.

Arrhythmia

Arrhythmias are abnormalities in heart rhythms, which can be either too fast or too slow. They can result from abnormalities of the initiation of an impulse or impulse conduction or a combination of both. Here is the latest research on arrhythmias.

Related Papers

American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists
Mara PoulakosTosin David
© 2022 Meta ULC. All rights reserved